dermaPACE Pivotal Phase III Clinical Trial Results for Diabetic Foot Ulcer Treatment to Be Presented at the Symposium on Advanced Wound Care (SAWC) Spring 2011.
Business Wire › April 12, 2011
Linked as:
Extract
dermaPACE Pivotal Phase III Clinical Trial Results for Diabetic Foot Ulcer Treatment to Be Presented at the Symposium on Advanced Wound Care (SAWC) Spring 2011.
ALPHARETTA, Ga. -- SANUWAVE Health, Inc. (OTCBB: SNWV) (www.sanuwave.com), an emerging medical technology company focused on the development and commercialization of noninvasive, biological response activating devices in regenerative medicine, today announced that study results from the Company's pivotal Phase III, Investigational Device Exemption (IDE) clinical trial with dermaPACE([R]) to treat diabetic foot ulcers wi...
See the full content of this document
Sponsored links
